You just read:

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma

News provided by

U.S. Food and Drug Administration

Sep 28, 2018, 16:29 ET